SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval
CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after securing regulatory approval in China for its Aprepitant Injection, a next generation NK 1 antagonist aimed at preventing postoperative nausea and vomiting in adults.
See our latest analysis for CSPC Pharmaceutical Group.
Investors appear to be responding to a mix of product approvals, the 2025 earnings release and ongoing capital returns. A 1 year total shareholder return of 80.59% and a 90 day share price return of 9.22%...